Harbin Pharmaceutical Group Co., Ltd. (600664.SS) Stock Analysis
High-risk turnaround hinges on GNC revival as Harbin Pharma battles domestic decline and global uncertainty.
Overview
Harbin Pharmaceutical Group (HPGC), a long-established Chinese pharmaceutical company, has reshaped its business through the high-stakes acquisition of GNC—a move that positions the firm as both a domestic pharmaceutical leader and a global health and wellness retailer. This transformation introduces significant opportunities for international expansion, notably in China's growing health market, but also exposes HPGC to new complexities, including integration risks and heightened geopolitical scrutiny. The investment case now rests on HPGC's ability to stabilize the struggling GNC business and generate new growth amidst domestic headwinds, as success or failure in these endeavors will define the company’s long-term outlook.